This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Authoring team

Consult expert advice.

Treatment options depend on the stage of the disease.

  • Stage Ia-IIa
    • skin directed treatment options include topical steroids, topical chemotherapy (nitrogen mustard, carmustine), phototherapy (UVA, UVB)
  • Stage IIb
    • as for Stage Ia-IIa +/- localised radiotherapy
    • as for Stage Ia-IIa +/- biological response modifiers (retinoids/interferon)
    • total skin electron beam therapy
    • single or multi-agent chemotherapy
  • Stage III
    • options include:
      • extracorporeal photochemotherapy
      • single or multi-agent chemotherapy
      • as for Stage Ia-IIa +/- biological response modifiers, total skin electron beam therapy, localised radiotherapy
  • Stage IV
    • options include systemic chemotherapy; radiotherapy and palliative skin directed treatment

A systematic review concluded (1):

  • lack of high-certainty evidence to support decision making in the treatment of MF
  • PUVA is commonly recommended as first-line treatment for MF, and we did not find evidence to challenge this recommendation
  • absence of evidence to support the use of intralesional IFN-alpha or bexarotene in people receiving PUVA and an absence of evidence to support the use of acitretin or ECP for treating MF

NICE state that (2):

  • chlormethine gel is recommended as an option for treating early stage (stage 1A, 1B, and 2A) mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adults

Notes (3):

  • mechlorethamine (also known as chlormethine) or nitrogen mustard (NM) has a primary role in the early stages of the skin-limited disease and has been studied for its efficacy in MF since 1959
  • NM is a topical chemotherapeutic alkylating agent that affects rapidly dividing cells
    • gel formulation is associated with irritation, hyperpigmentation, pruritus, erythema, and contact dermatitis

Reference:

  • Valipour A et al. Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews 2020, Issue 7. Art. No:CD008946. DOI: 10.1002/14651858.CD008946.pub3.
  • NICE (August 2021). Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
  • Liner K, Brown C, McGirt LY. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. Drug Des Devel Ther. 2018;12:241-254.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.